2 Vial Sizes | Kanjinti (trastuzumab) 420 mg & 150 mg | Amgen

You are leaving Kanjinti.EU website and entering another Amgen website

You are leaving Kanjinti.EU website and entering another Amgen website

You are now leaving Kanjinti.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

PROVIDES 2 VIAL SIZES
(420 MG AND 150 MG)

THE ONLY TRASTUZUMAB OFFERING AN ADDITIONAL VIAL SIZE

Beyond excellence in manufacturing and supply, and the comprehensive totality of evidence for KANJINTI®, Amgen offers value added features and services to address your daily practice needs.
One of these unique value-added benefits is an additional vial size (420 mg in addition to the 150 mg).1
The larger vial size* delivers key benefits:
Higher flexibility
to manage different patient weights, reducing wastage and delivering savings
Time savings
in the preparation of the product2
May reduce the risk
of medical errors
Less storage space
needed
Possibility to enhance
the automated preparation of the compound
In addition, KANJINTI® offers the same innovative features that Amgen offers for its other products, such as traceability through use of a flag label and sophisticated packaging to combat tampering and counterfeits.
* When larger doses are required, preparation can be done from a single vial, creating efficiency by reducing the number of vials requiring reconstitution, thereby reducing foaming and potential medication errors.
** Images of vials are not actual size.
  1. KANJINTI® Summary of Product Characteristics, May 2018.
    http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/004361/WC500249707.pdf.
  2. KARAKOÇ MD. Turk J Pharm Sci. 2017;14:304-310.

Home
banner

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.